Kane Biotech (TSE:KNE) has released an update.
Kane Biotech Inc. has achieved ISO 13485:2016 MDSAP Quality Certification, allowing it to seek regulatory approval for its medical products in Canada, Australia, New Zealand, and Brazil. This certification, which acknowledges Kane’s commitment to quality and patient safety, is a significant step for the company as it aims to improve the quality of chronic wound care products and expand its portfolio in these international markets.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
